GET DAILY SIGNALSAmerican Shared Hospital Services (AMS) Stock Falls -17% Over the Past Month After Earnings Miss
Key Takeaways
- AMS shares have fallen roughly 17% over the past 30 days, sliding from about $1.27 to approximately $1.06, with the decline accelerating after a third-quarter earnings miss.
- A weaker-than-expected third-quarter report was the primary near-term catalyst, as the company posted EPS of -$0.09 versus a consensus estimate of $0.03.
- Revenue still advanced 6% year over year to $7.62 million in the third quarter, but a widening net loss weighed on sentiment.
- Over the last quarter, the stock has declined roughly 29% from around $1.50 in mid-August, extending a longer slide from its 52-week high of $2.39.
- Broader pressures include persistent net losses, elevated leverage, a credit-agreement forbearance with Fifth Third Bank, and the low trading liquidity typical of a micro-cap stock.
- For additional detail, explore AMS Price Targets, Earnings, and Forecast pages.
- Readers tracking momentum signals can also explore Tickeron's Trending AI Robots.
Company Background and Market Position
American Shared Hospital Services (AMS) provides turnkey stereotactic radiosurgery and advanced radiation therapy solutions for cancer treatment centers, health systems, and cancer networks across North and South America. Founded in the early 1980s and headquartered in San Francisco, the company operates through two segments: Equipment Leasing and Direct Patient Services. Its portfolio includes Gamma Knife radiosurgery systems and a proton beam radiation therapy (PBRT) system, along with planning, installation, reimbursement, and marketing support.
The company leases nine Gamma Knife systems and one proton beam system, and it directly owns and operates radiosurgery facilities that treat patients on a per-procedure basis. This direct-services model has become the company's fastest-growing revenue stream, with facilities in Rhode Island and Puebla, Mexico, plus international Gamma Knife operations in Peru and Ecuador. I think investors follow AMS for its niche position in precision cancer treatment, though its small market capitalization and leveraged balance sheet make it a higher-risk holding. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Stock Price Performance: Last 30 Days vs. Quarter
Over the past 30 days, AMS shares have moved decisively lower. The stock traded near $1.27 in mid-October and has since declined to approximately $1.06, a drop of roughly 17%. Much of the damage occurred in a single session following the company's third-quarter earnings release, when the stock fell about 10% intraday as results came in below analyst expectations.
The quarterly trend tells a similar story on a larger scale. In mid-August, following a second-quarter report that beat revenue estimates, the stock traded near $1.50. Since then, shares have shed roughly 29%, reflecting sustained selling pressure rather than a single isolated event. The decline has taken AMS toward the lower end of its 52-week range of $1.14 to $2.39, underscoring how far the stock has retreated from prior highs.
What Drove the Recent Price Action
The clearest catalyst was the company's third-quarter earnings report, released in mid-November 2026. AMS reported a diluted loss of $0.09 per share, missing the consensus estimate of $0.03 by $0.12. Revenue came in at $7.62 million, up 6% year over year but essentially in line with expectations, and the net loss attributable to shareholders widened to $620,000. The earnings shortfall triggered the sharpest single-day decline of the period.
Beyond earnings, the stock has been pressured by the company's ongoing capital structure challenges. During the third quarter, AMS entered into a Third Amendment to its Credit Agreement and Forbearance Agreement with Fifth Third Bank and secured $2.0 million in subordinated financing from an entity controlled by its Executive Chairman. While management framed these moves as providing near-term liquidity, they also highlight the company's elevated leverage and financing constraints. With only about 6.65 million shares outstanding, limited institutional ownership, and thin average daily volume, relatively small shifts in sentiment can produce outsized price swings.
Performance Drivers Over the Past Quarter
The multi-month decline reflects a combination of execution progress and persistent financial headwinds. Operationally, the business has been expanding: first-half and nine-month revenue grew at a double-digit pace, driven by a roughly 27% increase in Direct Patient Services revenue and stronger proton beam utilization. Yet the company has remained unprofitable on a GAAP basis, and rising operating costs, credit-loss reserves, and higher legal and banking expenses tied to the Fifth Third forbearance have kept margins under pressure.
The second-quarter report in August illustrated the mixed picture. AMS beat revenue estimates with $8.43 million, up 19% year over year, but still posted an EPS miss. Investors have since become more cautious about the company's path to profitability and its ability to refinance or extend its debt obligations, contributing to a steady drift lower across the quarter rather than any single negative catalyst.
Key Factors to Watch Going Forward
Several factors are likely to shape the outlook for AMS. The company's ability to return to profitability and expand adjusted EBITDA will remain central, particularly as it manages its forbearance agreement and works toward longer-term capital structure alternatives. Progress on its San Javier joint venture in Guadalajara, Mexico, where a Gamma Knife Esprit upgrade is expected to support patient treatments beginning in mid-2027, represents a potential growth opportunity. New Rhode Island projects that have received certificate-of-need approvals also offer a multi-year pipeline.
Investors should monitor proton beam treatment volumes and reimbursement trends, international Gamma Knife procedure growth, and any updates on debt refinancing. A single analyst maintains a $4.00 price target, well above the current share price, but the company's small size, ongoing losses, and leverage mean the risks remain substantial. As with any investment, the stock's low liquidity and sensitivity to quarterly results warrant careful consideration.
Exploring Tickeron’s AI Tools for Market Insights
In my research process, I often review Tickeron’s AI Trading Bots to see how automated strategies are performing across different timeframes and market conditions. The Trending AI Robots list provides a curated view of top-performing bots, which can help identify active momentum signals without manual effort. It has become a useful reference point when evaluating names like AMS alongside broader sector trends.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
AMS's Indicator enters downward trend
The Aroon Indicator for AMS entered a downward trend on November 11, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 210 similar instances where the Aroon Indicator formed such a pattern. In 143 of the 210 cases the stock moved lower. This puts the odds of a downward move at 68%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AMS as a result. In 93 of 138 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 67%.
The Moving Average Convergence Divergence Histogram (MACD) for AMS turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 29 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 62%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 65%.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where AMS's RSI Oscillator exited the oversold zone, 6 of 9 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 67%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +6.40% 3-day Advance, the price is estimated to grow further. Considering data from situations where AMS advanced for three days, in 127 of 200 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.
AMS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 5 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.334) is normal, around the industry mean (204.532). P/E Ratio (-4.462) is within average values for comparable stocks, (21.572). Projected Growth (PEG Ratio) (0.070) is also within normal values, averaging (2.498). Dividend Yield (0.164) settles around the average of (0.154) among similar stocks. P/S Ratio (0.313) is also within normal values, averaging (2.688).
The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 76 (best 1 - 100 worst), indicating slightly worse than average price growth. AMS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AMS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provideer of turnkey technology solutions for advanced radio surgical and radiation therapy services
Industry HospitalNursingManagement